Cardiac sodium channel palmitoylation regulates channel availability and myocyte excitability with implications for arrhythmia generation by Pei, Zifan et al.
ARTICLE
Received 21 Jan 2016 | Accepted 22 May 2016 | Published 23 Jun 2016
Cardiac sodium channel palmitoylation regulates
channel availability and myocyte excitability with
implications for arrhythmia generation
Zifan Pei1, Yucheng Xiao1, Jingwei Meng2, Andy Hudmon1,2,3 & Theodore R. Cummins1,3
Cardiac voltage-gated sodium channels (Nav1.5) play an essential role in regulating cardiac
electric activity by initiating and propagating action potentials in the heart. Altered Nav1.5
function is associated with multiple cardiac diseases including long-QT3 and Brugada
syndrome. Here, we show that Nav1.5 is subject to palmitoylation, a reversible post-trans-
lational lipid modiﬁcation. Palmitoylation increases channel availability and late sodium
current activity, leading to enhanced cardiac excitability and prolonged action potential
duration. In contrast, blocking palmitoylation increases closed-state channel inactivation and
reduces myocyte excitability. We identify four cysteines as possible Nav1.5 palmitoylation
substrates. A mutation of one of these is associated with cardiac arrhythmia (C981F), induces
a signiﬁcant enhancement of channel closed-state inactivation and ablates sensitivity to
depalmitoylation. Our data indicate that alterations in palmitoylation can substantially control
Nav1.5 function and cardiac excitability and this form of post-translational modiﬁcation is
likely an important contributor to acquired and congenital arrhythmias.
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V
oltage-gated sodium channels (VGSCs) are responsible
for initiation and propagation of action potentials in
excitable cells (for example, neurons, muscles and
myocytes)1–3. VGSCs consist of the a pore forming subunit
and one or more b auxiliary subunits that regulate sodium ion
ﬂux through the membrane. The cardiac subtype Nav1.5 is
predominantly expressed in the heart and plays an essential role
in regulating cardiac electric activity4. VGSC isoforms can differ
in their intrinsic biophysical properties (that is, rapid activation
and inactivation), but their activity can also be regulated by
post-translational modiﬁcations. Although some modiﬁcations
(such as phosphorylation) have been extensively studied,
the regulation of VGSCs by lipid modiﬁcations is poorly
understood.
Palmitoylation has been recognized as an important post-
translational mechanism for the regulation of various membrane
proteins, but our knowledge of how palmitoylation regulates ion
channels is limited5. Protein S-Palmitoylation involves the
addition of a 16-carbon palmitic acid chain to an intracellular
cysteine residue through a thioester linkage6. S-Palmitoylation is
a reversible process that can dynamically regulate protein life
cycle and function5. Multiple enzymes that facilitate the
palmitoylation process have been identiﬁed in recent years7,8
and these palmitoyltransferases form a diverse family of proteins
(23 members in mammals)9–11. The reverse process, depal-
mitoylation, is mediated by acyl-protein thioesterases12.
Palmitoylation is thought to play an important role in the
biosynthesis pathway of sodium and potassium channels13,14,
trafﬁcking of glutamate channels15,16 and the spatial organization
of aquaporin channels17. However, few studies have focused on
how palmitoylation directly alters channel biophysical activity at
the membrane. Palmitoylation of the intracellular linker between
domains II and III in Kv1.1 has been shown to increase the
intrinsic voltage sensitivity of the channel18. In 1987, brain
sodium channel palmitoylation was identiﬁed to occur in the
early stages of biosynthesis14. Electrophysiological data indicates
that two putative palmitoylation sites in a Nav1.2 channel clone
likely regulate brain sodium channel activity as well as
modulating toxin-channel afﬁnity19. A general hypothesized
mechanism is that the palmitate molecules attached to cysteine
residues in ion channels interact with the membrane lipids,
changing the lipid membrane environment surrounding the
targeted channel as well as impacting protein conﬁguration, thus
potentially modulating channel activity.
Although palmitoylation is likely an important regulator of
ion channel activity, evidence for the direct inﬂuence of
palmitoylation on cellular excitability, and its potential
involvement in cardiac sodium channelopathies, is lacking. In
our study, we show that palmitoylation changes have profound
impact on cardiac myocyte excitability. Using both biochemical
and electrophysiological assays, we demonstrate that Nav1.5 is
palmitoylated in both a heterologous expression system and in
native cardiac tissue. We show that modulation by palmitoyla-
tion substantially regulates Nav1.5 inactivation, and we identify
potential palmitoylation sites regulating this process. A
previously identiﬁed disease mutation in Nav1.5 associated
with cardiac arrhythmia illustrates how the potential loss of
palmitoylation at this crucial residue alters channel inactivation
and dysregulates myocyte excitability to contribute to cardiac
disease. In summary, our experimental data and computer
simulation results suggest that palmitoylation not only has
profound impact on Nav1.5 activity and cardiac excitability, but
is also likely to play a previously unrecognized role in both
inherited and acquired cardiac channelopathies. Palmitoylation
of Nav1.5 may represent a new target in treating cardiac
diseases.
Results
Regulation of cardiac excitability by palmitoylation. Cardiac
excitability and arrhythmia generation is critically dependent on
the gating of multiple ion channel proteins. Recent evidence
suggests that the activity of numerous proteins, including ion
channels, may be modulated by the palmitoylation, one of the
most common post-translational lipid modiﬁcations. We asked if
manipulating protein palmitoylation in cardiac myocytes would
alter excitability. In control myocyte cultures, we routinely
observed numerous beating cells on each coverslip andB70% of
the myocytes that exhibited inward current in voltage-clamp
recordings generated spontaneous action potentials in current
clamp recordings (Fig. 1a). To decrease protein palmitoylation,
we incubated the cells with 2-Br-palmitate (25 mM). 2-Br-palmi-
tate is a nonmetabolizable palmitate analogue that is broadly used
as a palmitoyltransferase inhibitor, inhibiting palmitoylation and
thus leads to protein depalmitoylation20,21. Although at least
one study demonstrated that 2-Br-Palmitate may also inhibit
acyl-protein thioesterase activity22, this inhibition is not predicted
to be appreciable at 25 mM. After 24 h treatment with 2-Br-
palmitate, spontaneously beating myocytes were rarely observed
and none of the cells that exhibited inward sodium current in
voltage-clamp recordings was able to generate action potentials in
current clamp recordings (Fig. 1a). In contrast, we observed
distinct effects when myocytes were cultured in the presence of
additional palmitate (10 mM palmitic acid), the primary substrate
for palmitoylation. Although palmitic acid is structurally similar
to 2-Br-palmitate (Supplementary Fig. 1), it does not inhibit
palmitoyltransferase. Furthermore, our biochemistry data
indicates that excess palmitic acid can enhance Nav1.5
palmitoylation (see below). In contrast to 2-Br-palmitate
treatment, palmitic acid did not abolish beating but rather
many cells in the palmitic acid treated group displayed
spontaneous beating and action potentials that were readily
recorded from myocytes in this treatment group. The recorded
action potentials from the palmitic acid treatment group
exhibited an increased action potential duration (APD) and
a decreased ﬁring frequency (Fig. 1b–e) compared with the
non-treatment group. Interestingly, when comparing the
spontaneous action potential waveforms, we often observed an
early after-depolarization (EAD)-like phenomenon in the
palmitic acid treatment group (Fig. 1f,g), but not under the
control condition (Fig. 1h). These data suggest that reducing
palmitoylation in cardiac myocytes attenuates excitability and
enhancing palmitoylation (by increasing the availability of
substrate) can increase cardiomyocyte excitability.
Nav1.5 is post-translationally modiﬁed by palmitoylation. Our
results suggest that enhanced palmitoylation of cardiomyocyte
proteins could potentially lead to abnormal cardiac electric
activity. Cardiac sodium channels are a critical determinant of
electrogenesis in myocytes and therefore we directly investigated
if Nav1.5 was palmitoylated using multiple end points. First, we
used a non-radioactive acyl biotin exchange (ABE) method23–25
that detects thioester-linked protein acyl-modiﬁcations, most
commonly palmitoylation, in both cardiac tissues and HEK293
cells stably expressing Nav1.5 recombinant channels. Our results
indicate that Nav1.5 is S-palmitoylated in cardiac tissues (Fig. 2a,
Supplementary Fig. 2a). The signal in the ‘þ ’ (hydroxylamine
treatment) lane shows the component captured by streptavidin,
which reﬂects the S-palmitoylated protein before hydroxylamine
cleavage. The absence of a signal in the ‘ ’ (control)
lane provides conﬁdence that the signal in the ‘þ ’ lane is
indeed dependent on hydroxylamine activity and reﬂects
S-palmitoylation. Caveolin, which has been previously reported
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to be palmitoylated in cardiac tissue23,26, was used as a positive
control (Supplementary Fig. 2). Calmodulin, which does not
contain any cysteine residues, was used as a negative control and
shows that there is no signal for non-palmitoylated proteins
(Supplementary Fig. 2). Our results also suggest that Nav1.5 is
modiﬁed by S-palmitoylation in HEK293 cells (Fig. 2b). Although
palmitoylation is the most common acylation modiﬁcation of
proteins in mammalian cells, it is not the only possible
modiﬁcation detected by the ABE method. As a direct measure
of Nav1.5 palmitoylation, we metabolically labelled HEK293 cells
stably expressing Nav1.5 with tritiated palmitate. Nav1.5 was
immunoprecipitated and palmitoylation was detected by
autoradiography following SDS-polyacrylamide gel electro-
phoresis. These experiments clearly demonstrated that tritium
labelled palmitic acid was incorporated into Nav1.5 channels as
identiﬁed by immunoprecipitation and western blot analysis
(Fig. 2c upper and middle panels). Using a third measurement of
palmitoylation, we were also able to detect Nav1.5 palmitoylation
with copper-catalysed click chemistry (Supplementary Fig. 3).
This method is based on metabolic incorporation of alkynyl
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Figure 1 | Palmitoylation alters cardiomyocytes excitability. All data are shown as mean±s.e.m. (a) Number of cells that are excitable myocytes. Only
cells that exhibited inward sodium current were analysed. Seven out of 10 cells (70%) in the control group ﬁred spontaneous action potentials. None of the
10 cells in the 2-Br-palmitate (2BP) group were able to generate action potentials. (b) Representative action potential traces of cardiomyocytes with (blue)
and without (black) palmitic acid treatment. Palmitic acid(PA) treatment increases the APD. (c) Averaged APD measurements from the spontaneous
ﬁring myocytes. Averaged APD is 563ms in the control group and 890ms in the palmitic acid treatment group. The difference is statistically signiﬁcant
(n¼ 5, P¼0.001 and unpaired Student’s t-test). (d) Averaged APD measurements of single action potential waveform elicited by 2ms stimulus pulses.
APD is 330.4ms in the non-treatment group and 572.8ms in the palmitic acid treatment group. The difference is statistically signiﬁcant (n¼ 5, P¼0.01
and unpaired Student’s t-test). (e) Firing frequency in control group and palmitic acid treatment group. The ﬁring frequency is 1.2±0.10 in the control
group and 0.79±0.11 in the palmitic acid treatment group. The difference is statistically signiﬁcant (n¼ 8, P¼0.03 and unpaired Student’s t-test).
(f–g) Spontaneous action potential recorded from palmitic acid treatment group. EAD phenomenon is indicated with arrows. The results are representative
of at least three independent experiments. (h) Cardiomyocyte spontaneous action potential generated under non-treatment condition. The action potential
ﬁring is in a constant rate with no ectopic ﬁring observed.
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derivatives of palmitic acid that can be detected with direct in-gel
ﬂuorescence analysis. Altogether, three lines of biochemical
evidence support the conclusion that Nav1.5 is indeed
palmitoylated in both the heterologous expression system and
native cardiac tissue.
Enhancement and inhibition of Nav1.5 palmitoylation.
To determine if Nav1.5 palmitoylation can be regulated in
living cells, we incubated the Nav1.5 stable HEK293 cells with
2-Br-palmitate, the palmitoyltransferase inhibitor that can effec-
tively induce protein depalmitoylation20. We treated the Nav1.5
stable cells with various concentrations of 2-Br-palmitate for 24 h
and then performed the ABE assay. Results of this experiment
indicate that 2-Br-palmitate can eliminate Nav1.5 palmitoylation
in HEK293 cells at concentrations as low as 25 mM (Fig. 3a). Next
we pre-incubated the cells with palmitic acid for 24 h to increase
the substrate of palmitoylation. The results show that the addition
of palmitic acid was able to substantially enhance Nav1.5
palmitoylation at concentrations as low as 10 mM (Fig. 3b).
Overall, these data demonstrate that the two distinct forms of
palmitate exert opposite effects on regulating Nav1.5 protein
palmitoylation. These data conﬁrm that Nav1.5 palmitoylation is
subject to bidirectional regulation and provided a paradigm that
we took advantage of to study how site-speciﬁc palmitoylation of
Nav1.5 modulates the biophysical properties of the channel.
Palmitoylation modulates cardiac myocyte sodium currents.
To investigate if bidirectional alterations in the palmitoylation of
cardiac sodium channels might contribute to the observed
changes in cardiomyocyte excitability, we examined voltage-gated
sodium currents in the cultured cardiomyocytes from neonatal
rats. In these experiments, we blocked potassium and calcium
currents to record isolated voltage-gated sodium currents. Our
results demonstrate that neither 2-Br-palmitate nor palmitic acid
treatment signiﬁcantly changed the rate of sodium current fast
inactivation (Fig. 4a) or current density (Fig. 4b, P40.05,
unpaired Student’s t-test) in myocytes, suggesting palmitoylation
might not play a major role in regulating cardiac sodium channel
surface expression. Interestingly, palmitic acid treatment, which
enhances palmitoylation of cardiac sodium channels, induced a
fourfold increase in the persistent component of the voltage-gated
sodium currents (Fig. 4c,d). Although the magnitude of the
inward persistent current was slightly o1% of the peak current
after palmitic acid treatment, this increase is similar to that
observed with several long-QT3 mutations27. An increase in these
small but powerful late currents is likely to contribute to the
prolonged APD- and EAD-like phenomenon shown in Fig. 1.
Moreover, palmitic acid treatment shifted the steady-state
inactivation to more depolarized voltages (Fig. 4e) and
enhanced recovery from inactivation for myocyte sodium
currents (Fig. 4f,g), which would also likely contribute to
enhanced excitability of cardiomyocytes. On the contrary, 2-Br-
palmitate induced a hyperpolarizing shift of steady-state
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Figure 2 | Cardiac sodium channels are post-translationally modiﬁed by
protein palmitoylation. Three distinct methods were utilized to detect
protein palmitoylation: acyl-biotin exchange (a,b), metabolic tritium labelling
(c) and click chemistry (Supplementary Fig. 3). The results are representative
of at least three independent experiments. (a) Nav1.5 is palmitoylated in
cardiac tissues, where ‘þ ’ (hydroxylamine treated group) indicates the
existence of protein palmitoylation on Nav1.5 channels and ‘ ’ (tris treated
group) serves as the negative experimental control. All the biotinylated
proteins (previously palmitoylated proteins) were immunoprecipitated using
a streptavidin pull down assay. A sodium channel pan antibody was used to
detect transfected or endogenous sodium channel proteins. (b) Nav1.5 is also
palmitoylated in HEK293 cells with stable expression of Nav1.5 channels.
(c) Nav1.5 palmitoylation was identiﬁed after tritium-labelled palmitic acid
treatment. Upper panel: tritium-labelled palmitoylated Nav1.5 was detected in
HEK293 cells stably expressing Nav1.5, but not in control HEK293 cells;
Middle panel: Nav1.5 was shown in western blot analysis using the same
samples; Lower panel: comparable amount of actin from the same samples
was shown in western blot analysis.
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Figure 3 | Palmitate lipid treatments alter Nav1.5 palmitoylation in
HEK293 cells that stably express Nav1.5. The results are representative of
at least three independent experiments. (a) 2-Br-palmitate(2BP) treatment
inhibited Nav1.5 palmitoylation at 25mM. (b) Palmitic acid(PA) treatment
increased Nav1.5 palmitoylation at 10mM.
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inactivation (Fig. 4h) and slowed the recovery of inactivation
for sodium current in cardiomyocytes (Fig. 4f,g). The
parameters of activation and inactivation curves, obtained
from Boltzmann equation ﬁts, are summarized in Table 1.
While palmitic acid treatment induced biophysical changes in
sodium current properties that would increase electrical activity
in myocytes, the large negative shift in the voltage dependence
of inactivation observed with 2-Br-palmitate is predicted to
effectively reduce channel availability as well as cardiomyocyte
excitability.
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Figure 4 | 2-Br-palmitate(2BP) and palmitic acid(PA) treatments alter biophysical properties of voltage-gated sodium currents in cardiomyocytes.
Data from the 24-h pretreatment of 2-Br-palmitate and palmitic acid are shown in green and blue, respectively. Black lines and open symbols identify data
from the control condition. All data are shown as mean±s.e.m. (a) Normalized current with and without palmitate lipid treatment. Cells were depolarized
to  20mV from a holding potential of  100mV. Inset indicates representative traces of Nav1.5 current in cardiomyocytes. (b) Comparison of normalized
current density. Current density was measured as the peak current divided by cell capacitance (nA/pF). Box and Whisker plots were generated to compare
the mean difference. The box was drawn from the 25th to 75th percentiles. Tukey method was used to determine the whiskers and outliers (shown as
individual points above the whiskers). In the non-treatment group, mean current density is 0.43±0.04 nA/pF, n¼ 35; In the 2-Br-palmitate treated group,
mean current density is 0.30±0.08 nA/pF, n¼ 16. In the palmitic acid treatment group, the current density is 0.56±0.10 nA/pF, n¼ 13. No signiﬁcant
statistical difference is observed in 2-Br-palmitate group (P¼0.13, unpaired Student’s t-test) or palmitic acid group (P¼0.18, unpaired Student’s t-test).
(c,d) Persistent current (c) and statistical analysis (d) comparing the control condition and treatment groups. The persistent current was measured as the
percentage of peak current. The persistent current is 0.19±0.16% (control); 0.04±0.30% (2-Br-palmitate); 0.83±0.24%(palmitic acid). n¼ 6–10.
The difference between control group and palmitic acid treatment group is statistically signiﬁcant (P¼0.037). (e) Comparison of sodium channel
voltage dependence of activation and steady-state inactivation between control (black, open symbol, n¼ 29) and palmitic acid treatment (blue, n¼ 16).
(f,g) Comparison of sodium channel recovery from inactivation with 2-Br-palmitate (n¼ 9) and palmitic acid treatment (n¼9). The recovery time duration
is from 0 to 2,048ms ((f) plotted in the log form) and 0–50ms (g). (h) Comparison of sodium channel voltage dependence of activation and steady-state
inactivation between control (black, open symbol, n¼ 29), 2-Br-palmitate treatment (green, n¼ 17).
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Palmitoylation alters Nav1.5 properties in HEK293 cells. To
explore the mechanism by which palmitoylation regulates cardi-
omyocyte sodium currents, we investigated whether modulation
of palmitoylation alters the functional properties of Nav1.5
channels expressed in HEK293 cells. The main advantage of these
cells is that they do not express signiﬁcant levels of other ion
channels and can be readily used to express recombinant Nav1.5
channels in isolation. We incubated the HEK293 cells expressing
Nav1.5 with 25 mM 2-Br-palmitate for 24 h and performed whole-
cell electrophysiological recordings. The rate of fast inactivation
and the conductance–voltage relationship were not signiﬁcantly
altered by 2-Br-palmitate (Fig. 5a) compared with the control
group. However, 2-Br-palmitate treatment substantially shifted
the steady-state inactivation of wild-type (wt) Nav1.5 to more
hyperpolarized voltages (Fig. 5a, middle). In addition, 2-Br-
palmitate treatment slightly slowed the rate for recovery from
inactivation (Fig. 5a, right). These effects were also observed with
shorter (4 h) 2-Br-palmitate treatments (Supplementary Fig. 4).
By contrast, palmitic acid, which enhances Nav1.5 palmitoylation
in HEK293 cells (Fig. 3b), shifted the voltage dependence of
steady-state inactivation in the depolarizing direction, enhancing
channel availability and increased the rate of recovery from
inactivation (Fig. 5b). Palmitic acid also slightly shifted the
conductance–voltage relationship. Neither 2-Br-palmitate nor
palmitic acid seems to affect the Nav1.5 voltage dependence of
slow inactivation or recovery from slow inactivation (Fig. 5c–f).
The midpoint of the inactivation and activation curves are
summarized in Table 1 and representative current traces and
current–voltage plots under all three treatment conditions are
shown in Supplementary Fig. 5. These results replicate our
ﬁnding in cardiomyocytes, conﬁrming that Nav1.5 current
properties are indeed regulated by modulating palmitoylation and
that the HEK293 heterologous expression system serves as a
model system to further explore the molecular determinants for
this regulation.
Identiﬁcation of Nav1.5 cysteines that are palmitoylated. To
determine how Nav1.5 activity is regulated by palmitoylation,
we interrogated the channel sequence for potential modiﬁcation
sites. Although no single conserved sequence of palmitoylation
has been identiﬁed, the bioinformatics tool CSS-Palm 3.0
can predict which cysteines are potential palmitoylation sites28.
By comparing the similarity of amino acid sequence
surrounding cysteines with experimentally determined
palmitoylation sites, the entire Nav1.5 sequence was analysed
and four endogenous intracellular cysteine residues that are
highly predicted to be palmitoylated were identiﬁed (Fig. 6a,
Supplementary Table 1). These four cysteines are located in the
cytoplasmic linker between domains II and III, and three out of
four residues form a cysteine cluster (Fig. 6b). To further
investigate the functional role of these four endogenous
cysteines in regulating channel palmitoylation, we constructed
a mutant channel with these four cysteine residues substituted
to alanine residues using site-directed mutagenesis in an
attempt to eliminate endogenous palmitoylation. This mutant
channel construct, referred to as Nav1.5-AAAA, was used in
experiments described below to explore the molecular mecha-
nism contributing to palmitoylation associated functional
changes in Nav1.5 activity.
To assess the functional role of the four predicted
endogenous palmitoylation sites, we transiently transfected the
Nav1.5-AAAA channel into HEK293T cells and subsequently
treated the cells with 2-Br-palmitate. The results demonstrate
that 2-Br-palmitate does not alter Nav1.5-AAAA fast inactiva-
tion signiﬁcantly (Fig. 7a). Wild-type Nav1.5 was transiently
transfected into a second set of cells as a control. Treatment
with 2-Br-palmitate shifted the steady-state inactivation of
transiently transfected wt Nav1.5 in the hyperpolarized direc-
tion (Fig. 7b left), similar to that previously observed with the
Nav1.5 stable cell line. Interestingly, although chemical inhibi-
tion of palmitoylation still shifted steady-state inactivation of
Nav1.5-AAAA in the hyperpolarized direction (Fig. 7b, right;
Table 1), the effect was substantially smaller (o3mV)
compared with wt Nav1.5 (B17mV). The differential effect
implies that one or more of these four cysteines are crucial in
the regulation of Nav1.5 by palmitoylation. In addition, we
found that the midpoint (V½) of Nav1.5-AAAA steady-state
inactivation under control conditions was quite close to that of
wt Nav1.5 after 2-Br-palmitate treatment, leading us to
conclude that the cysteine to alanine substitution(s) alter
steady-state inactivation, probably through regulation of
palmitoylation on one or more of the four predicted cysteines.
To conﬁrm that the ablation of 2-Br-palmitate’s effect is due to
the alteration in palmitoylation status, we used the ABE assay to
assess palmitoylation of wt Nav1.5 and Nav1.5-AAAA channels.
Our results indicate that the substitution of cysteine residues to
alanine residues largely reduced the palmitoylation of the
Table 1 | Midpoint voltage of activation and steady-state inactivation with a standard Boltzmann distribution ﬁt
Activation Inactivation
V1/2 (mV) K (mV) V1/2 (mV) K (mV)
Nav1.5 stable  33.4±0.3 7.8±0.2  90.4±0.6 7.1±0.5
Nav1.5 stable 2BP  34.1±0.4 8.9±0.4*  103±0.5* 8.1±0.4*
Nav1.5 stable PA  29.9±0.4 7.7±0.4  83.4±0.4* 6.3±0.4
Nav1.5 transient 46.3±0.4 6.9±0.3  90.8±0.5 7.3±0.4
Nav1.5 transient 2BP  50.8±0.6 7.8±0.5  108.4±0.7* 9.7±0.6
Nav1.5-AAAA 48.2±0.4 8.1±0.4  103.4±0.7w 9.0±0.6
Nav1.5-AAAA 2BP  50.4±0.5 7.7±0.4  106.0±0.5 8.4±0.5
Nav1.5 C981F  50.2±0.5 8.1±0.4  100.2±0.5w 6.9±0.4
Nav1.5 C981F 2BP  52.6±0.4 7.3±0.4  100.7±0.7 8.3±0.6
Nav1.5 C981A 47.8±0.7 6.7±0.6  100.5±0.6w 7.9±0.5
Nav1.5 C981A 2BP 43.2±0.7 8.5±0.6  104.8±0.9 10.3±0.8
Nav1.5 cardiomyocytes  37.3±0.3 7.1±0.3  76.6±0.5 8.2±0.4
Nav1.5 cardiomyocytes 2BP 42.2±0.6 8.5±0.5*  99.4±0.6* 10.1±0.5*
Nav1.5 cardiomyocytes Palmitic acid  36.1±0.5 6.7±0.5  71.0±0.5* 7.3±0.5
*indicates Po0.05 compared with the corresponding non-treatment group. The two-tailed, Student’s t-test was used to study the statistical signiﬁcance.
windicates Po0.05 compared with wild-type group.
All data are shown as mean±s.e.m.
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channel (Fig. 7c). These data strongly support the hypothesis
that palmitoylation induced changes in Nav1.5 function is
produced by speciﬁc modiﬁcation of one or more of these four
endogenous cysteine residues.
Palmitoylation site associated with Nav1.5 disease mutation.
Numerous missense mutations in Nav1.5 have been identiﬁed in
individuals with cardiac arrhythmia. In a previously published
study, the missense mutation C981F was reported in patient
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samples submitted for long-QT syndrome genetic testing29
(Fig. 8a). Because this mutation occurs at one of the four
predicted palmitoylation sites, we developed a Nav1.5 construct
containing this mutation (Nav1.5-C981F) and investigated its
biophysical properties in HEK293T cells. A signiﬁcant shift of
steady-state inactivation to more hyperpolarized voltages was
observed when comparing to wt Nav1.5 (Fig. 8b). No change in
the rate of open channel fast inactivation was detected (Fig. 8c)
and the C981F mutant channel did not exhibit enhanced
persistent current generation. To understand if altered
palmitoylation contributes to the shift of the inactivation curve,
we treated the Nav1.5-C981F transfected cells with 2-Br-
palmitate as in previous experiments. We found that 2-Br-
palmitate treatment had very little effect on Nav1.5-C981F
channel steady-state inactivation (Fig. 8d). To conﬁrm that the
effect is speciﬁcally due to the loss of the cysteine residue and not
to insertion of a bulky hydrophobic residue, we examined a
cysteine to alanine mutation at the same site. Nav1.5-C981A also
exhibited a hyperpolarized steady-state inactivation and revealed
insensitivity to 2-Br-palmitate treatment (Fig. 8e). Moreover, in
our study, both C981F and C981A exhibited very similar
properties to the Nav1.5-AAAA channel. This indicates that the
C981 site alone accounts for the major palmitoylation effect on
Nav1.5 steady-state inactivation, and is likely to be the most
important site among the four predicted cysteines. To further
conﬁrm the role of the C981 site and investigate the roles of other
cysteine residues, we also tested a Nav1.5 mutant with C981 intact
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and the other three cysteines mutated to alanines (Nav1.5-AAA).
Results with this mutant channel indicate that depalmitoylation
has a signiﬁcant effect on Nav1.5-AAA steady-state inactivation
(Fig. 8f). This effect was also seen in a single alanine mutation,
Nav1.5-C1178A (Fig. 8g). These results further validate the
critical and speciﬁc role of C981 palmitoylation in regulating
channel gating properties.
Simulations of Nav1.5 palmitoylation and cell excitability. To
assess if the observed changes in sodium channel activity might
indeed be sufﬁcient to account for the changes in cardiomyocyte
excitability shown in Fig. 1, we replicated the 2-Br-palmitate and
palmitic acid induced changes in Nav1.5 in a computational
model of a human myocyte and assessed the impact on action
potential generation. The computational model, previously
implemented in the NEURON simulation environment30, was
minimally adjusted (Supplementary Fig. 6). The consequences of
increased palmitoylation (palmitic acid treatment) were simulated
by shifting the voltage dependence of inactivation by 5mV in the
positive direction and increasing the non-inactivating component
by B4-fold (Fig. 9a–c). The consequences of Nav1.5
depalmitoylation were simulated by shifting the voltage
dependence of inactivation 24mV in the negative direction and
slightly decreasing the non-inactivating component (Fig. 9a–c). In
the model myocyte, the simulated sodium currents with enhanced
palmitoylation substantially increased the APD (Fig. 9d). On the
contrary, when we simulated the effects of sodium channel
depalmitoylation, the model myocyte completely failed to
generate action potentials, consistent with our ﬁnding in
d
f g
I/I
m
ax
I/I
m
ax
I/I
m
ax
1.0
0.5
0.0
–150 –100 –50 0
–150 –100 –50 0 –150 –100 –50 0
Nav1.5
Nav1.5 AAA C1178A
C1178A 2BPNav1.5 AAA 2BP
C981F
C981F 2BP
0.0
0.5
1.0
0.0
0.5
1.0
0.0
0.2
0.4
0.8
1.0
0.6
0.0
0.2
0.4
0.8
1.0
0.6
0.0
0.2
0.4
0.8
1.0
0.6
G
/G
m
ax
G
/G
m
ax
G
/G
m
ax
Voltage (mV)
Voltage (mV) Voltage (mV)
e
I/I
m
ax
–150 –100 –50 0
Nav1.5
C981A
C981A 2BP
0.0
0.5
1.0
0.0
0.2
0.4
0.8
1.0
0.6
G
/G
m
ax
Voltage (mV)
a
b
Position Sequence Region
DII−DIII981
1.0
0.5
I/I
m
ax
0.0
–150 –100 –50 0
0.0
Nav1.5
C981F
c
0.0
20 40 60
Nav1.5
C981F
Time (ms)
–0.5
–1.0N
or
m
a
liz
e
d 
cu
rre
nt
0.2
0.4
0.8
1.0
0.6
G
/G
m
ax
Voltage (mV)
KRTTWDFFCGLLRQR
Figure 8 | Loss of cysteine mutation from patient with cardiac arrhythmia affects biophysical properties of Nav1.5. All data are shown as mean±s.e.m.
(a) Long-QT3 mutation (C981F, red) that can potentially abolish the endogenous palmitoylation in wild-type Nav1.5. (b) Comparison of voltage dependence
of activation and steady-state inactivation of wild-type Nav1.5 (black) and C981F mutant channels (red). n¼ 10. (c) Normalized current of wild-type Nav1.5
channel (black) and Nav1.5-C981F (red). Current traces were averaged data from 9 measurements. (d) Nav1.5-C981F channel activation and steady-state
inactivation with (green) and without (black) 2-Br-palmitate(2BP) treatment. n¼ 10. (e) Nav1.5-C981A voltage dependence of activation and steady-state
inactivation with (green) and without (black) 2-Br-palmitate treatment. The dotted line indicates the wild-type Nav1.5 steady-state inactivation. n¼ 7. (f,g)
2-Br-palmitate treatment (green) affect Nav1.5-AAA (f) and Nav1.5-C1178A (g) voltage dependence of activation and steady-state inactivation. n¼ 10.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12035 ARTICLE
NATURE COMMUNICATIONS | 7:12035 | DOI: 10.1038/ncomms12035 | www.nature.com/naturecommunications 9
cultured cardiomyocytes (Fig. 1a). This indicates the changes in
cardiac sodium channel activity due to alterations in
palmitoylation are sufﬁcient to generate the altered excitability
that we observed when palmitoylation was manipulated in
primary myocyte cultures.
Discussion
In recent years, the progress of ion channel palmitoylation
research has been enhanced by the development of new
biochemical and proteomics tools31,32 and the identiﬁcation of
palmitoyltransferases10,11. Although a few studies have indicated
that VGSCs in the brain are subject to palmitoylation14,19, it had
not previously been determined if sodium channels from other
excitable tissues are also subject to modulation by palmitoylation.
More importantly, how palmitoylation would affect cellular
excitability in any tissue was unclear. This study, for the ﬁrst
time, utilized both biochemical and electrophysiology techniques
for investigation of palmitoylation in VGSC modulation. Our
data, in conjunction with computer simulations, indicate that
palmitoylation can substantially regulate cardiac sodium
currents and that alterations in Nav1.5 palmitoylation are likely
to play important roles in acquired and inherited cardiac
channelopathies.
Palmitoylation is a reversible modiﬁcation that regulates
various steps during protein life cycle, including trafﬁcking,
stability and membrane association. Palmitoylation regulation of
membrane binding plays a role for many peripheral membrane
proteins33,34 and affects trafﬁcking and surface expression of ion
channels35,36. In our study, palmitoylation induced a small
change in current density (Fig.4). However, this difference was
not statistically signiﬁcant, indicating that palmitoylation has
negligible impact on cell surface expression of Nav1.5. Instead,
our data demonstrate that Nav1.5 palmitoylation has profound
impact on channel availability by regulating the voltage
dependence of steady-state inactivation in both HEK293 cells
(Fig. 5) and cardiomyocytes (Fig. 4). Based on the relative
magnitude of the shifts induced by palmitic acid (þ 6mV) and
2-Br-palmitate ( 20mV) compared with control experiments,
these data could be an indication that as many as two-thirds of
the channels are palmitoylated under our control conditions.
However, several studies have identiﬁed crosstalk between
palmitoylation and other post-translational modiﬁcations in ion
channel proteins15,37–39 and it is therefore unclear if all Nav1.5
channels are able to be palmitoylated in our experiments.
Four endogenous palmitoylation sites that were likely to
regulate Nav1.5 palmitoylation were identiﬁed using a palmitoy-
lation prediction algorithm. These four residues are all located in
the second major cytoplasmic loop (Fig. 6). Mutation of these
four cysteines to alanines had essentially the same effect on
steady-state inactivation as 2-Br-palmitate treatment did on wt
Nav1.5, and the Nav1.5-AAAA channels were insensitive to
modulation by 2-Br-palmitate treatment (Fig. 7), indicating that
one or more of these cysteines are responsible for the change in
inactivation observed with wt Nav1.5 depalmitoylation. The
Nav1.5 C981F and C981A channels had almost the same
inactivation properties as the Nav1.5-AAAA channel (Fig. 8),
indicating that C981 is likely to be the crucial site at which
palmitoylation modulates inactivation of Nav1.5. However, it is
unclear how palmitoylation of C981 impacts the voltage
dependence of steady-state inactivation. We noticed that all of
the sites that are implicated in Nav1.5, as well as the endogenous
palmitoylation sites predicted in Nav1.2 to modulate steady-state
inactivation, are located in the cytoplasmic linker between
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domains II and III. One possibility is that by increasing
association of this linker to the membrane, palmitoylation may
alter the movement of the domain III voltage-sensor, which is
important for inactivation40. Although our data clearly indicate
that C981 palmitoylation is crucial to the gating changes that we
observed, we were unable to generate a stable cell line containing
only a C981 mutant channel for further biochemical analysis.
Therefore we cannot rule out the possibility that one or more of
the other three predicted sites are palmitoylated and that this
might modulate other properties of Nav1.5 in cardiac myocytes.
Our data also indicate that palmitoylation of Nav1.5 should
have a pronounced impact on cardiomyocyte excitability.
Inhibiting palmitoylation in myocytes greatly reduced voltage-
gated sodium channel availability. In contrast, enhancing
palmitoylation increased APD and induced aberrant action
potential ﬁring. While multiple cardiac proteins involved in the
cardiac action potential might be palmitoylated, our computer
simulations indicate that changes in Nav1.5 gating due to
palmitoylation are sufﬁcient to cause the excitability changes
that we observed in myocytes. However, we still cannot rule out
that changes in palmitoylation of potassium and calcium
channels might also contribute to the altered action potential
activity we observed in myocytes. Despite this potential caveat,
the C981F mutation provides additional evidence that alteration
of Nav1.5 palmitoylation is likely to impact cardiac action
potentials and contribute to arrhythmogenesis. This mutation
was identiﬁed in the genomic DNA sample of a patient referred
for long-QT syndrome clinical genetic testing29. In a patient
cohort of 2,500 unrelated cases, 110 distinct mutations were
identiﬁed in SCN5A that were absent in the 42,600 control
alleles. Although most of the patients were believed to have been
referred due to a long-QT phenotype, some were apparently
referred because they had Brugada syndrome phenotypes29.
Based on the biophysical analysis, we predict that the patient with
the C981F mutation more likely had a Brugada or overlapping
syndrome phenotype, although unfortunately deﬁnitive
phenotypic data was not available in the study that reported the
C981F mutation29. Interestingly, we also identiﬁed four long-QT3
mutations in the literature (R34C, R1175C, F1473C and R1644C)
that our analysis predicts could add an additional palmitoylation
site on Nav1.5, suggesting that enhanced palmitoylation may
contribute to the biophysical alterations induced by some long-
QT mutations. In contrast to C981F effects, Bankston et al.27
reported that the F1473C Nav1.5 mutation, a long-QT mutation
associated with a severe clinical phenotype, had similar
biophysical consequences as those we observed with palmitic
acid treatment. The F1473C mutation shifted the midpoint of
Nav1.5 inactivation in the depolarizing direction by 9mV and
increased persistent (late) currents toB0.6% of the peak current.
Furthermore, they used a computer model of a ventricular
myocyte to show that the combined shift in steady-state
inactivation and increase in persistent current amplitude is
sufﬁcient to double the duration of the ventricular action
potential. All together these data suggest that while
depalmitoylation of a key Nav1.5 cysteine can result in reduced
cardiac excitability similar to that observed with Brugada
syndrome, excessive palmitoylation of Nav1.5 can lead to
enhanced cardiac activity similar to that observed with long-QT
syndrome mutations.
In summary, our data show that palmitoylation of Nav1.5 can
substantially modulate the inactivation properties of cardiac
sodium currents and lead to bidirectional alterations in cardiac
excitability. The existence of disease-related mutations that alter
potential palmitoylation sites indicate that modulation of cardiac
sodium channel palmitoylation is likely to be an unrevealed
mechanism of cardiac arrhythmia generation. A previous study
indicates that palmitoylation of cardiac proteins increases during
reoxygenation of anoxic cardiac tissue41, and thus enhanced
palmitoylation of cardiac sodium channels could contribute to
reperfusion induced arrhythmias. Evidence indicates that
palmitoylation can also be altered by diet, stress and redox
signalling42. Although the vast majority of long-QT3 and
Brugada syndrome mutations may not directly alter Nav1.5
palmitoylation, increased palmitoylation of Nav1.5 is predicted to
enhance EADs and arrhythmias in patients with long-QT3 and
reduced palmitoylation of Nav1.5 is expected to exacerbate
symptoms in patients with Brugada syndrome; thus regulation of
Nav1.5 activity by palmitoylation could be important in multiple
cardiac pathophysiological conditions. Brain sodium channel
activity is also likely to be regulated by palmitoylation43 and
altered palmitoylation has been implicated in a number of
neurological disorders44. Overall, alterations in palmitoylation of
VGSCs are likely to have profound effects on cellular excitability
in a variety of tissues and pathophysiological conditions.
Methods
Chemicals and reagents. 2-Br-palmitate and palmitic acid were obtained from
Sigma-Aldrich.
Site-directed mutagenesis. hNav1.5 constructs were introduced into
pcDNA3.1(þ ) with the cytomeglovirus (CMV) promoter using HindIII and XbaI
restriction enzyme sites45. Speciﬁc mutation sites were introduced using the
QuikChange II XL site-directed mutagenesis kit according to the manufacturer’s
instruction. All the constructs were sequenced (ACGT Inc.) to conﬁrm mutation
sites.
Cell culture and transfection. HEK293 and HEK293T cells (ATCC CRL-1573
and CRL-3216, respectively) were cultured in Dulbecco’s Modiﬁed Eagle Medium
(Life Technologies) supplemented with 10% foetal bovine serum (FBS). Cells were
transfected using the calcium phosphate precipitation method. Cells were plated on
glass coverslips in 24-well plates and the mixture of DNA and calcium phosphate
was added to the medium and patch-clamp recordings were performed 24–48 h
after transfection.
Acyl biotin exchange method. Performed as previously described23,25 with minor
modiﬁcations. Brieﬂy, cell lysate was treated overnight using N-ethylmaleimide to
block free cysteines while rotating at 4 C to ensure complete cysteine alkylation.
Next day, the insoluble component was discarded after centrifuge at 13,500g for
5mins. The cell lysate was washed by chloroform–methanol precipitation to
remove excess chemicals. The protein interface was washed twice using methanol.
After the last centrifugation, protein was dissolved in 500ml PBS containing 1%
SDS. The soluble protein was divided into two equal groups, each containing 250 ml
and treated with either NH2OH(0.7M hydroxylamine, 1mM biotin, 0.2% Triton
X-100 and 1 protease inhibitor) or tris (200mM tris, 1mM biotin, 0.2% Triton
X-100 and 1 protease inhibitor) solution. The reaction was carried out in a dark
environment for 1 h. The remaining chemicals were removed using a chloroform–
methanol wash and resolubilized in PBS containing 1% Triton X-100 and
0.2% SDS. The biotinylated proteins were captured by streptavidin-Sepharose
(GE Healthcare) beads in an incubation overnight at 4 C. The beads were
washed four times with PBS containing 1% Triton X-100 and 0.2% SDS the next
day. Electrophoresis loading buffer (LDS containing 2% -mercaptoethanol) was
added to each sample and heated for 10min at 80 C.
Copper (I)-catalysed azide-alkyne cycloaddition reaction (click chemistry).
Untransfected HEK293 cell and HEK293 cells stably expressing Nav1.5 channels
were cultured in DMEM with 10% FBS. Cells were then incubated in 17-ODYA
labelling media (DMEM with 10% dialyzed FBS (Gemini Bio Products) and
25mM 17-octadecynoic acid (Cayman Chemical)) for 4 h, washed with D-PBS
(Thermoﬁsher Scientiﬁc), and lysed with cell lysis buffer (20mM Hepes, 20mM
NaCl, 5mM EDTA, 1% Triton X-100 and 1 protease inhibitor cocktail set V
(Millipore)). Cleared lysates were immunoprecipitated with anti-Nav1.5 pan
antibody and protein G-Sepharose for 4 h. The beads were washed three times in
lysis buffer and resuspended with 44 ml D-PBS. Click chemistry reagents contain-
ing1mM CuSO4 (Sigma-Aldrich), 1mM tris(2-carboxyethyl)phosphine (Sigma-
Aldrich), 100 mM tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (Sigma-
Aldrich) and 1 ml IRDye 680RD Azide (Thermoﬁsher Scientiﬁc) were then added to
the beads. After 1 h incubation at room temperature, the beads were washed three
times with D-PBS and treated with 1X SDS gel loading buffer. The supernatants
were separated into two equal amounts of 25 ml samples. For control experiments,
1.25 ml of 50% stock of hydroxylamine (pH7.0) was added into one of the two equal
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amount samples to remove the thioester-dependent labelling. The sample mix was
then incubated at room temperature for 1 h, heated at 85 C for 10min and
analysed by standard SDS-polyacrylamide gel electrophoresis gel electrophoresis.
In-gel ﬂuorescence of probe-labelled proteins was detected by Li-Cor Odyssey
CLx Imager.
Metabolic labelling and detection of Nav1.5 palmitoylation. HEK293 cells
stably expressing human Nav1.5 channels were cultured in 100mm dishes, while
co-cultures of untransfected HEK293 cells were used as negative controls. Each
dish was labelled with 120mCi/ml [3H] palmitic acid (PerkinElmer) in regular
culture medium overnight. The medium was removed the following day and cells
were rinsed three times with PBS. Cell lysates were collected and added to the
protein G agarose bead, which was prepared by coupling Nav1.5 pan antibody
overnight. After 4 h incubation, the lysate was removed, the protein-G beads were
washed three times with lysis butter (20mM Hepes, 20mM NaCl, 5mM EDTA,
1% Triton X-100 and 1 protease inhibitor cocktail set V(Millipore)), and proteins
were eluted from the beads using 4X LDS sample buffer with 2% beta-mercap-
toethanol. Samples were then analysed according to the standard denaturing PAGE
protocol (Life Technologies, Novex Gel System). The gel was washed three times
with hot water and stained with Coomassie Blue for 1 h. To increase the sensitivity
of tritium detection, protocols using EN3HANCE (PerkinElmer) was followed
based on manufacturer’s instructions. To precipitate the ﬂuor in the gel, gel was
washed with 10% PEG 800 and 1% glycerol with agitation for 30min. To further
prevent the gel from cracking, the gel was incubated in gel dying buffer (30%
Ethanol, 10% glycerol) for 30min and transferred onto Whatman ﬁlter paper for
vacuum drying (ThermoSavant). Dried gels were exposed to Biomax high-sensi-
tivity ﬁlm (Sigma-Aldrich) and stored at  80 C freezer for B3 weeks before
developing the ﬁlm.
Gel electrophoresis and western immunoblotting. Samples were solubilized in
4 LDS sample buffer and b-mercaptoethanol. Gel electrophoresis and protein
transfer was performed according to the standard protocol (Life Technologies).
Sodium channel pan antibody (Sigma, 1:1,000 diluted) was used as a primary
antibody to detect Nav1.5 signal. In the cardiac tissue study, caveolin3 antibody
(BD Biosciences, 1:5,000 diluted) was used to detect caveolin expression in the
cardiac tissues. The ﬂuorescently labelled secondary antibody (IRDye 800CW goat
anti-mouse, 1:5,000 diluted) was obtained from Li-Cor. The uncropped scans of
gels and western blots of the representative images are shown in Supplementary
Figs 7 and 8.
Whole-cell patch clamp recordings on HEK293 cells. Whole-cell sodium
currents were recorded using the method and standard solutions46,47. Brieﬂy, glass
pipettes were pulled and polished with resistance between 0.9 and 2MO.The
standard external bathing solution for sodium current recording contained
(in mM) 140 NaCl, 1 MgCl2, 1 CaCl2, 3 KCl and 10 HEPES, pH 7.3 adjusted with
1N NaOH. Osmolarity of the solution was 276mOsm l 1. The standard pipette
solution contained (in mM) 140 CsF, 10 NaCl, 1.1 EGTA and 10 HEPES, pH 7.3
(adjusted with CsOH) and the osmolarity of the solution was 293mOsm l 1. Once
a gigaohm or greater seal was formed between the cell of interest and the recording
pipette, the whole-cell conﬁguration was obtained using gentle suction pulses.
Recordings were started B5min after forming whole-cell conﬁguration to allow
sufﬁcient equilibration of the intracellular solution and the pipette solution. In the
conductance–voltage relationship studies, the cells were held at  100mV then a
100-ms pulse from  100mV to þ 45mV with 5mV increments was used to elicit
the currents. In steady-state inactivation studies, cells were held at  100mV and
then stepped to an inactivating prepulse from  150mV to  10mV with 10mV
increments for 500ms. The channels that remain available after each inactivating
prepulse were evaluated by the peak current produced during a test pulse to 0mV
for 20ms. In the recovery from inactivation protocol, 500ms depolarization pulse
to þ 20mV was induced to fully inactivate the channel, and recovery was assessed
by a test pulse from  100 to 0mV with a varying time between pulses (0–50ms).
Cardiac tissue lysate preparation. The use of animals was in compliance with the
Guide for the Care and Use of Laboratory Animals published by the US National
Institutes of Health and was approved by the Indiana University School of
Medicine Animal Care and Use Committee. For ABE experiments, heart tissue
(300mg) from Sprague Dawley rats was homogenized in 10ml lysis buffer (20mM
Hepes, 20mM NaCl, 5mM EDTA, 1% Triton X-100 and 1 protease inhibitor
cocktail set V). The homogenate was centrifuged at 4 C at 13,200g, and the
supernatant was collected. Aliquots of supernatant were stored at  80 C.
Cardiomyocyte isolation and culture. Experiments were performed following
previous protocols47, with slight modiﬁcations. Sprague Dawley rat pups of
postnatal day 1 were used in the harvest, isolation and culture of rat
cardiomyocytes. PBS containing 0.5mgml 1 collagenase was used as the digestion
solution. The ventricle tissues were cut into pieces and digested in the 37 C water
bath for 45min with a gentle mix every 5min. The cell suspension was collected
every 15min and fresh digestion solution was added each time. Collected cells were
plated in 10 cm cell culture dishes for 2 h to allow ﬁbroblast cells attach and then
transferred to 24-well plates with gelatin pre-coated coverslips. Cells were
incubated under normal cell culture conditions (37 C, 5% CO2) in Dulbecco’s
Modiﬁed Eagle Medium supplemented with 10% FBS. After 24 h incubation, the
culture medium was replaced with a low serum medium (0.5% horse serum,
0.5% FBS) to prevent hypertrophy. Cardiomyocytes were cultured for up to 72 h.
Whole-cell patch clamp recordings on cardiomyocytes. The extracellular
solution of whole-cell voltage-clamp recordings contains (mM): 120 NaCl, 1.2
MgCl2, 1.5 CaCl2, 10 Hepes, 10 tetraethylammonium-chloride, 5.0 sucrose, 5.0
glucose and 0.05 CdCl2, pH was adjusted to 7.4 with NaOH. Osmolarity of the
solution was 283mOsm l 1. Tetraethylammonium-chloride and CdCl2 were used
to block potassium and calcium currents in myocytes to focus on recording whole-
cell sodium currents. The pipette solution contained: 120 CsF, 5.0 NaCl, 2.0 MgCl2,
10 Hepes and 10 EGTA. pH was adjusted to 7.3 with CsOH (osmolarity of the
solution was 276mOsm l 1). For the whole-cell current clamp recordings on
cardiomyocytes, the bath solution contained (mM): NaCl 126, KCl 5.4, Hepes 10,
NaH2PO4 0.33, MgCl2 1.0, CaCl2 1.8 and glucose 10. pH was adjusted with NaOH
to 7.3 (osmolarity of the solution was 300mOsm l 1). The pipette solution used in
current-clamp studies contained (mm): KCl 20, potassium aspartate 110, MgCl2
1.0, Hepes 5.0, EGTA 10 and Na2-ATP 5.0. pH was adjusted to 7.2 with KOH
(osmolarity of the solution was 295mOsm l 1). Action potentials were elicited by
2ms stimulus pulses at a frequency of 1 kHz. Spontaneous action potential
generation was recorded given the current input at 0 pA. Action potential
measurements were started 5min after establishing the whole-cell conﬁguration.
Cardiac myocyte simulation. Computer models of cardiac AP ﬁring48,49 were
employed to simulate the impact of the consequences of the changes in channel
gating induced by sodium channel palmitoylation. The cardiac myocyte model was
adapted from that previously implemented by Ingemar Jacobson in the NEURON
simulation environment30 (which is available at http://senselab.med.yale.edu/
ModelDB/ShowModel.asp?model=3800). The only changes made to the
mathematical formulations used in the model were to the voltage-dependent
sodium current (Naf in the original model). We ran simulations with (1) wild-type
Nav1.5 currents, (2) Nav1.5 currents with simulated 2-Br-palmitate treatment and
(3) Nav1.5 currents with simulated palmitic acid treatment. A Markov model of
Nav1.5 (ref. 50), based on the Hodgkin-Huxley formulation of Nav1.5 in the
original cardiac model of AP ﬁring48,49, was used as it is more amenable to
implementation of the palmitic acid and 2-Br-palmitate effects. This formulation
also included slow inactivation states. Supplementary Fig. 6 shows a diagram for
the Markov model of the simulated Nav1.5 conductance and Supplementary
Table 2 shows the transition rate expressions for Nav1.5 and the currents
simulating the two treatment groups.
Data Analysis. Whole-cell patch clamp data were analysed using the Pulseﬁt
(v 8.65, HEKA Electronic), GraphPad Prism (GraphPad Software Inc.) and origin
pro 8 (Originlab Corp). All data points are shown as mean±s.e.m., and n is
presented as the number of the separate experimental cells. Steady-state activation
and inactivation curves were ﬁtted using Boltzmann equation: I(V)¼Offsetþ
{amplitude/[1þ exp((VV1/2)/Z)]}, in which V1/2 represents midpoint of activa-
tion and inactivation curve. V stands for the test potential and Z represents the
slope factor. Two tailed, Student’s t-tests were used to study the statistical differ-
ence of the channel functional parameters with and without channel depalmitoy-
lation, including current density, half maximal activation/inactivation, slope factor,
recovery rate. P values o0.05 was considered as statistically signiﬁcant difference.
Data Availability. The data that support the ﬁndings of this study are available
from the corresponding author on request.
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